Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue

被引:91
作者
Magklara, A
Scorilas, A
Stephan, C
Kristiansen, GO
Hauptmann, S
Jung, K
Diamandis, EP
机构
[1] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[3] Humboldt Univ, Univ Hosp Charite, Dept Urol, Berlin, Germany
[4] Humboldt Univ, Univ Hosp Charite, Dept Pathol, Berlin, Germany
关键词
D O I
10.1016/S0090-4295(00)00621-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To study quantitatively the relative expression of human glandular kallikrein 2 (hK2) and prostate-specific antigen (PSA) in paired (from the same patient) cancerous and noncancerous prostatic tissue to evaluate whether these proteins are overexpressed or underexpressed in cancer. Methods. We studied 14 patients who underwent radical retropubic prostatectomy for prostate cancer. Cancerous and adjacent normal tissues were excised and then extracted to prepare cytosolic extracts. The extracts were analyzed for total protein, and for hK2 and PSA using sensitive and specific immunofluorometric procedures. Results. PSA was present in the prostatic extracts at about 50 to 100 times higher amounts than hK2. The correlation between PSA and hK2 values was good. Both prostate kallikreins were expressed more in noncancerous than in cancerous prostatic tissue. Conclusions. Our results demonstrated that both PSA and hK2 are down-regulated in prostate cancer compared with noncancerous tissue. The degree of down-regulation was higher for PSA than for hK2. The mechanism and physiologic consequences of this down-regulation are unknown. UROLOGY 56: 527-532, 2000. (C) 2000, Elsevier Science Inc.
引用
收藏
页码:527 / 532
页数:6
相关论文
共 30 条
[1]  
Black MH, 1999, CLIN CHEM, V45, P790
[2]  
Black MH, 2000, BRIT J CANCER, V82, P361
[3]   Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial [J].
Catalona, WJ ;
Partin, AW ;
Slawin, KM ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
deKernion, JB ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Subong, ENP ;
Parson, RE ;
Gasior, GH ;
Loveland, KG ;
Southwick, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1542-1547
[4]   Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases [J].
Darson, MF ;
Pacelli, A ;
Roche, P ;
Ritttenhouse, HG ;
Wolfert, RL ;
Saeid, MS ;
Young, CYF ;
Klee, GG ;
Tindall, DJ ;
Bostwick, DG .
UROLOGY, 1999, 53 (05) :939-944
[5]   Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker [J].
Darson, MF ;
Pacelli, A ;
Roche, P ;
Rittenhouse, HG ;
Wolfert, RL ;
Young, CYF ;
Klee, GG ;
Tindall, DJ ;
Bostwick, DG .
UROLOGY, 1997, 49 (06) :857-862
[6]   Prostate-specific antigen: Its usefulness in clinical medicine [J].
Diamandis, EP .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1998, 9 (08) :310-316
[7]   The new human kallikrein gene family: Implications in carcinogenesis [J].
Diamandis, EP ;
Yousef, GM ;
Luo, LY ;
Magklara, A ;
Obiezu, CV .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2000, 11 (02) :54-60
[8]  
Ferguson RA, 1996, CLIN CHEM, V42, P675
[9]   Antiangiogenic activity of prostate-specific antigen [J].
Fortier, AH ;
Nelson, BJ ;
Grella, DK ;
Holaday, JW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) :1635-1640
[10]  
Gallas J. A. C., 1990, International Journal of Modern Physics C (Physics and Computers), V1, P181, DOI 10.1142/S0129183190000098